Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07285902 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With Obesity

StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Recruiting to Active, Not Recruiting Enrollment target: estimated 750 to confirmed 572 · Site details revised at 2 of 2 sitesv3 Show 2 more changesShow less
    • Enrollment target: estimated 750 to confirmed 572
    • Site details revised at 2 of 2 sites
  2. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Dec 2025 to Dec 25, 2025 · Site details revised at 2 of 2 sitesv2 Show 2 more changesShow less
    • Start date changed from estimate of Dec 2025 to Dec 25, 2025
    • Site details revised at 2 of 2 sites
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is a multicenter, randomized, open-label, parallel-controlled, phase III study to compare the efficacy, safety, and tolerability of HRS9531 versus semaglutide once weekly (QW) in adult subjects with obesity
Trial Details
NCT Number NCT07285902
Lead Sponsor Fujian Shengdi Pharmaceutical Co., Ltd.
Conditions Obesity
Enrollment 572 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov